for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up
Healthcare Sector

BRIEF-AB Science Initiates Phase 2 Study Evaluating Masitinib In Combination With Isoquercetin For Treatment Of COVID-19

May 6 (Reuters) - AB Science SA:

* REG-AB SCIENCE GRANTED AUTHORIZATION BY ANSM TO INITIATE PHASE 2 STUDY EVALUATING MASITINIB IN COMBINATION WITH ISOQUERCETIN FOR THE TREATMENT OF COVID-19

* AB SCIENCE SA - STUDY WILL ENROLL 200 PATIENTS AT MEDICAL CENTERS IN FRANCE AND OTHER COUNTRIES

* AB SCIENCE SA - ANNOUNCES INITIATION OF A PHASE 2 STUDY EVALUATING MASITINIB IN COMBINATION WITH ISOQUERCETIN FOR TREATMENT OF COVID-19, FOLLOWING RAPID REVIEW AND ACCEPTANCE RECEIVED FROM FRENCH MEDICINE AGENCY, ANSM.

* AB SCIENCE SA - PRIMARY OBJECTIVE IS TO IMPROVE CLINICAL STATUS OF PATIENTS AFTER 15 DAYS OF TREATMENT. Source text for Eikon: Further company coverage: (Gdansk Newsroom)

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up